Illustrations on the mode of action of a BTK inhibitor in CLL (chronic lymphocytic leukemia) on the B cells in the lymph nodes.

In chronic lymphocytic leukemia, the number of B cells is abnormally elevated.The lymph nodes are swollen due to the insertion of B cells. The active substance "Ibrutinib" blocks the interaction of BTK (Brutone Tyrosine Kinase) and transcription factor NFkB in the B cells, which enables cell death and thereby reduces their number. As more and more B-cells and also BTK are produced, a continuous intake of the drug is necessary to reduce the number of B-cells.

Content: 5 illustrations

Utilization: printed information folder for sales force

Specifications: Print, DIN A5 / 300dpi

ClientSir Prise & Lady Buy / Janssen Swiss

The rights of use of the illustrations shown are with the respective clients. The images are protected with a watermark.

 

 CLL wirkstoff b zellen ntk

The drug binds to the BTK and prevents interaction with the transcription factor NFkB

 

 CLL permanente abgabe wirkstoff b zelle

Because BTK is still being re-produced by the B cell, the drug must be taken continuously

 

 skizze cll lymphknoten b zellen

Rough sketch of the images for usage in pre-production